1. Home
  2. TRVI vs PEB Comparison

TRVI vs PEB Comparison

Compare TRVI & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

SELL

Current Price

$12.50

Market Cap

1.8B

Sector

Health Care

ML Signal

SELL

Logo Pebblebrook Hotel Trust of Beneficial Interest

PEB

Pebblebrook Hotel Trust of Beneficial Interest

HOLD

Current Price

$21.08

Market Cap

2.0B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRVI
PEB
Founded
2011
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
2019
2009

Fundamental Metrics

Financial Performance
Metric
TRVI
PEB
Price
$12.50
$21.08
Analyst Decision
Strong Buy
Hold
Analyst Count
11
16
Target Price
★ $28.18
$19.57
AVG Volume (30 Days)
★ 2.5M
2.2M
Earning Date
11-12-2026
10-29-2026
Dividend Yield
N/A
★ 0.20%
EPS Growth
★ 31.91
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $1,475,544,000.00
Revenue This Year
N/A
$0.81
Revenue Next Year
N/A
$1.91
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1.53
52 Week Low
$9.82
$9.99
52 Week High
$20.22
$21.26

Technical Indicators

Market Signals
Indicator
TRVI
PEB
Relative Strength Index (RSI) 36.03 69.08
Support Level $11.70 $17.50
Resistance Level $13.55 N/A
Average True Range (ATR) 0.66 0.62
MACD 0.13 0.15
Stochastic Oscillator 44.81 91.82

Price Performance

Historical Comparison
TRVI
PEB

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

About PEB Pebblebrook Hotel Trust of Beneficial Interest

Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under the Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.

Share on Social Networks: